Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI-456908
- Development stage
- Discontinued
- Lead developer
- Boehringer Ingelheim
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
BI-456908 is a dual agonist of the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R), developed by Boehringer Ingelheim. It was one of several candidates, including survodutide (BI 456906), evaluated for the treatment of metabolic disorders such as obesity and type 2 diabetes. In preclinical studies, BI-456908 was assessed for its pharmacological profile, including its effects on heart rate and its ability to engage both receptor targets to promote weight loss and improve metabolic parameters. Ultimately, Boehringer Ingelheim prioritized survodutide for clinical development, and BI-456908 remained a research-stage compound.
02
Targets
GLP1R (GLP-1R)GCGR (Glucagon receptor)
Beyond the preview
Go deeper on BI-456908.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI-456908.